1.76 USD
▲+0.03+1.73%
盘后 2.19 0.00%
2026-09-16
市值
$57.79M
市盈率
—
EPS
-1.71
股息率
—
52 周区间
1.28 – 9.50
成交量
58.58K
Beta
1.83
目标价
14.00
52W 低 1.2852W 高 9.50
价格走势
公司简介
Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders. Its lead product candidates include IMC-1, a combination of famciclovir and celecoxib that has completed Phase 2b clinical trial to treat fibromyalgia; Halneuron, which is in Phase 2b clinical trial for the treatment of chemotherapy-induced neuropathic pain and cancer pain, as well as pre-clinical trial for acute surgical pain; and IMC-2, a combination of valacyclovir and celecoxib intended t...